Identification of a cholesterol metabolism-related signature based on KIF20A and NDC80 for prognostic stratification and immunotherapy prediction in hepatocellular carcinoma.

Yu Yan, Zhenguo Liu, Dawei Zhou, Jiafeng Zou, Xinyu Liu

Abstract read

In one paragraph

Article in Cancer biomarkers : section A of Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu YanDepartment of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Zhenguo LiuDepartment of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Dawei ZhouDepartment of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Jiafeng ZouDepartment of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Xinyu LiuDepartment of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0009-0003-7644-8274

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundThe heterogeneity of hepatocellular carcinoma (HCC) complicates diagnosis and treatment, and previous prognostic models have failed to yield satisfactory results. Given that the metabolic reprogramming of cholesterol plays a crucial role in the pathogenic mechanism of hepatocellular carcinoma, this study was conducted as a breakthrough point.MethodsUtilizing multi-cohort data from TCGA, ICGC, and GEO, we screened Cholesterol metabolism-related genes (CMRGs) to construct a CMRG-derived prognostic model based on two key genes:

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCholesterolKinesinsLiver NeoplasmsNuclear ProteinsHumansImmunotherapyNomogramsPrognosisTumor MicroenvironmentBiomarkers, TumorCholesterolKIF20A protein, humanKinesinsNuclear Proteinscholesterol metabolismhepatocellular carcinomaimmunotherapyprognostic signature

Identifiers

PMID42685023

DOI10.1177/18758592261479725

PMCPMC13539014

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.